Analysis of naltrexone and its metabolite 6-beta-naltrexol in serum with high-performance liquid chromatography

BMC Research Notes

Hannu Alho¹  Pirjo Lillsunde²  Kari Ariniemi²  David Sinclair²  Tuuli Lahti³  Pekka Heinälä⁴ 

[1] Research Unit of Substance Abuse Medicine, University of Helsinki, Helsinki, Finland;National Public Health Institute, Helsinki, Finland;THL, PL 30, 00271, Helsinki, Finland;Finnish Foundation for Alcohol Studies, Helsinki, Finland

关键词: Alcoholism;    High-performance liquid chromatography;    6-β-naltrexol;    Naltrexone;   

Others  :  1165935
DOI  :  10.1186/1756-0500-5-439

 received in 2012-01-03, accepted in 2012-08-02,  发布年份 2012

【 摘 要 】

Background

Naltrexone has been proven to be an effective treatment option for the treatment of alcohol dependency. In this article we introduce a reliable and simple method developed for the simultaneous determination of naltrexone and 6-β-naltrexol in human serum by using high-performance liquid chromatography (HPLC).

Findings

Liquid-liquid extraction with butyl acetate from basic solutions (pH 9) was chosen for extraction with nalorphine as an internal standard (IS). Analytes were back-extracted from organic solvent into perchloric acid. The acid extract was chromatographed by HPLC with a reverse-phase ODS-column and electrochemical detector. The mobile phase was a NaH₂PO₄-solution with acetonitrile as an organic modifier and octanesulphonic acid and tetraethylammonium hydrogen sulphate as ion-pair reagents. The recovery of the extraction method was 48% for naltrexone and 75% for 6-β-naltrexol. The limit of quantification was 5.0 ng/ml for naltrexone and 1.0 ng/ml for 6-β-naltrexol. The analysed concentrations of naltrexone differed from the theoretic concentrations by 0.7 to 2.3% and those of 6-β-naltrexol by 2.6%. The relative standard deviation of within-day assay was from 0.9 to 5.7% for naltrexone and from 0.8 to 4.2% for 6-β-naltrexol; for the between-day assay it was 5.7% and 4.2%, respectively.

Conclusions

Our results indicate that the developed method is suitable for determination of naltrexone and 6-β-naltrexol in human serum.

【 授权许可】

   
2012 Heinälä et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Litten RZ, Allen JP: Advances in development of medications for alcoholism treatment. Psychopharmacology 1998, 139:20-33.
• [2]Volpicelli JR, Alterman AI, Hayashida M, O’Brien CP: Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 1992, 49:876-879.
• [3]O’Malley SS: Opioid antagonists in the treatment of alcohol dependence: Clinical efficacy and presentation of relapse. Alcohol Alcohol 1996, 1:77-81.
• [4]Anton RF, O’Malley SS, Ciraulo DC, Cisler RA, Couper D, Donovan DM, Gastfriend DR, Hosking JD, Johnson BA, LoCastro JS, Longabaugh R, Mason BJ, Mattson ME, Miller WR, Pettinati HM, Randall CL, Swift R, Weiss RD, Williams LD, Zweben AZ, for the COMBINE Study Research Group: Combined pharmacotherapies and behavioral interventions for alcohol dependence: The COMBINE Study: A Randomized Controlled Trial. JAMA 2006, 295:2003-2017.
• [5]Renault PF: Treatment of heroin-dependent persons with antagonists: Current status. Bull Narc 1978, 30:21-29.
• [6]Krupitsky E, Zvartau E, Masalov D, Tsoy M, Burakov A, Egorova V, Didenko T, Romanova T, Ivanova E, Bespalov A, Verbitskaya EV, Neznanov NG, Grinenko AY, O'Brien CP, Woody GE: Naltrexone with or without fluoxetine for preventing relapse to heroin addiction in St. Petersburg, Russia. J Subst Abuse Treat 2006, 31:319-328.
• [7]Crabtree BL: Review of naltrexone, a long-acting opiate antagonist. Clinical Pharmacology 1984, 3:273-280.
• [8]O’Malley S, Jaffe AJ, Chang G, Schottenfeld RS, Meyer RE, Rounsaville B: Naltrexone and coping skills therapy for alcohol dependence. Arch Gen Psychiatry 1992, 49:881-887.
• [9]Volpicelli JR, Rhines KC, Rhines JS, Volpicelli LA, Alterman AI, O’Brien CP: Naltrexone and alcohol dependence: role of subject compliance. Arch Gen Psychiatry 1997, 54:737-742.
• [10]Therapeutic Drugs 2: Therapeutic Drugs 2. Churchill Livingstone, London; 1993.
• [11]Wall ME, Brine DR, Perez-Reyes M: The metabolism of naltrexone in man. Naltrexone Research Monograph 1980, 28:105-131.
• [12]Wall ME, Brine DR, Perez-Reyes M: Metabolism and disposition of naltrexone in man after oral and intravenous administration. Drug Metab Dispos 1981, 9:369-375.
• [13]Verebey K, De Pace A, Jukofsky D, Volavka JV, Mule SJ: Quantitative determination of 2-hydroxy-3-methoxy-6-beta-naltrexol (HMN), naltrexone, and 6-beta-naltrexol in human plasma, red blood cells, saliva and urine by gas liquid chromatography. J Anal Toxicol 1980, 4:33-37.
• [14]McCaul ME, Wand GS, Sullivan J, Mummford G, Quigley J: Beta-naltrexol level predicts alcohol relapse. Alcohol Clin Exp Res 1997, 21:32A.
• [15]Bertolotti M, Ferrari A, Vitale G, Stefani M, Trenti T, Loria P, et al.: Effect of liver cirrhosis on the systemic availability of naltrexone in humans. J Hepatol 1997, 27:505-511.
• [16]Reuning RH, Ashcraft SB, Morrison BE: An electron-capture gas chromatographic assay for naltrexone in biological fluids. Naltrexone Research Monograph 1980, 28:25-35.
• [17]Davidson AF, Emm TA, Pieniaszek HJ: Determination of naltrexone and its major metabolite, 6-β-naltrexol, in human plasma using liquid chromatography with electrochemical detection. J Pharm Biomed Anal 1996, 14:1717-1725.
• [18]Zuccaro P, Altieri I, Betto P, Pacifici R, Ricciarello G: Determination of naltrexone and 6-β -naltrexol in plasma by high-performance liquid chromatography with coulometric detection. J Chromatogr 1991, 567:485-490.
• [19]Monti KM, Foltz RL, Chinn DM: Analysis of naltrexone and 6-β-naltrexol in plasma and urine by gas chromatography/negative ion chemical ionization mass spectrometry. J Anal Toxicol 1991, 15:136-140.
• [20]Huang W, Moody DE, Foltz RL: Determination of naltrexone and 6-β-naltrexol in human plasma by solid-phase extraction and gas chromatography- negative ion chemical ionization-mass spectrometry. J Anal Toxicol 1997, 21:252-257.
• [21]Nelson CC, Fraser MD, Wilfahrt JK, Foltz RL: Gas chromatography/ tandem mass spectrometry measurement of Δ9-tetrahydrocannabinol, naltrexone and their active metabolites in plasma. Ther Drug Monit 1993, 15:557-562.
• [22]Brünen S, Krüger R, Finger S, Korf F, Kiefer F, Wiedemann K, Lackner KJ, Hiemke C: Determination of naltrexone and 6beta-naltrexol in human blood: comparison of high-performance liquid chromatography with spectrophotometric and tandem-mass-spectrometric detection. Anal Bioanal Chem 2010, 396(3):1249-1257.
• [23]Brünen S, Vincent PD, Baumann P, Hiemke C, Havemann-Reinecke U: Therapeutic drug monitoring for drugs used in the treatment of substance-related disorders: literature review using a therapeutic drug monitoring appropriateness rating scale. Ther Drug Monit 2011, 33(5):561-572.